排序方式: 共有59条查询结果,搜索用时 15 毫秒
51.
SW Han Y Cha A Paquet W Huang J Weidler Y Lie T Sherwood M Bates M Haddad IH Park DY Oh KS Lee SA Im YJ Bang J Ro TY Kim 《PloS one》2012,7(7):e39943
Background
Lapatinib plus capecitabine is an effective treatment option for trastuzumab-refractory HER2-positive metastatic breast cancer. We have investigated the correlation between quantitative measures of HER2, p95HER2, and HER3 and treatment outcomes using lapatinib and capecitabine.Methods
Total HER2 (H2T), p95HER2 (p95), and total HER3 (H3T) expression were quantified in formalin-fixed paraffin-embedded samples using the VeraTag assays. Patients received lapatinib and capecitabine treatment following trastuzumab failure according to the Lapatinib Expanded Access Program. The association between the protein expression levels and clinical outcomes was analyzed.Results
A total of 52 patients were evaluable. H2T level was significantly higher in responders (median 93.49 in partial response, 47.66 in stable disease, and 17.27 in progressive disease; p = 0.020). Longer time-to-progression (TTP) was observed in patients with high H2T [p = 0.018, median 5.2 months in high (>14.95) vs. 1.8 in low (<14.95)] and high H3T [p = 0.017, median 5.0 months in high (>0.605) vs. 2.2 in low (<0.605)]. Patients having both high H2T and high H3T had significantly longer TTP [adjusted hazard ratio (HR) 0.38 (95% CI 0.20–0.73), p = 0.004] and overall survival [adjusted HR 0.46 (95% CI 0.24–0.89), p = 0.020]. No significant association between p95 and response or survival was observed.Conclusions
These data suggest a correlation between high HER2 and high HER3 expression and treatment outcome, while no significant difference was observed between clinical outcome and p95 expression level in this cohort of HER2-positive, trastuzumab-refractory metastatic breast cancer patients treated with lapatinib and capecitabine. 相似文献52.
53.
Yi Qiao Aaron R Quinlan Amir A Jazaeri Roeland GW Verhaak David A Wheeler Gabor T Marth 《Genome biology》2014,15(8)
Many tumors are composed of genetically divergent cell subpopulations. We report SubcloneSeeker, a package capable of exhaustive identification of subclone structures and evolutionary histories with bulk somatic variant allele frequency measurements from tumor biopsies. We present a statistical framework to elucidate whether specific sets of mutations are present within the same subclones, and the order in which they occur. We demonstrate how subclone reconstruction provides crucial information about tumorigenesis and relapse mechanisms; guides functional study by variant prioritization, and has the potential as a rational basis for informed therapeutic strategies for the patient. SubcloneSeeker is available at: https://github.com/yiq/SubcloneSeeker.
Electronic supplementary material
The online version of this article (doi:10.1186/s13059-014-0443-x) contains supplementary material, which is available to authorized users. 相似文献54.
Roel GW Verhaak Mathijs A Sanders Maarten A Bijl Ruud Delwel Sebastiaan Horsman Michael J Moorhouse Peter J van der Spek Bob Löwenberg Peter JM Valk 《BMC bioinformatics》2006,7(1):337-4
Background
Accurate interpretation of data obtained by unsupervised analysis of large scale expression profiling studies is currently frequently performed by visually combining sample-gene heatmaps and sample characteristics. This method is not optimal for comparing individual samples or groups of samples. Here, we describe an approach to visually integrate the results of unsupervised and supervised cluster analysis using a correlation plot and additional sample metadata. 相似文献55.
56.
57.
58.
Induction of ceruloplasmin synthesis by copper 总被引:2,自引:0,他引:2
P F Evans GW MAJORS W E Cornatzer 《Biochemical and biophysical research communications》1970,41(5):1120-1125
59.